Part­ner Bay­er push­es Ion­is' an­tithrom­bot­ic drug in­to mid-stage de­vel­op­ment

In 2015, when Io­n­is Phar­ma­ceu­ti­cals car­ried the ill-fat­ed name of Isis Phar­ma­ceu­ti­cals, it grant­ed Bay­er the li­cense to de­vel­op its pro­grams tar­get­ing Fac­tor XI — a clot­ting fac­tor pro­duced in the liv­er — for the treat­ment of clot­ting dis­or­ders. On Wednes­day, the Ger­man drug­mak­er sup­port­ed tak­ing one of their ex­per­i­men­tal an­ti-throm­bot­ic ther­a­pies in­to a Phase II tri­al, trig­ger­ing a $10 mil­lion mile­stone pay­ment for Io­n­is.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER